Category

View all Categories

Chinese Reports

Customer Service

Latest Research Alerts by Email

Sample Request | Order by Fax | Send to Friend | Printer Friendly

Cycloset (Type 2 Diabetes) ? Analysis and Forecasts to 2020

Chinese Version Report Link       Finished:      Product ID:E1619

Keywords

Cycloset Type 2 Diabetes Company

Abstract  

Summary
“Cycloset (Type 2 Diabetes) – Analysis and Forecasts to 2020” provides Cycloset sales estimates for US. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2010-2020). The report also includes information on Type 2 Diabetes market.
Note: This is a on-demand report and will be delivered within 2 business days (excluding weekends) of the purchase.
Scope
- Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
- Analysis and review of Cycloset including historical sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Cycloset including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecast for 2010-2020 for Cycloset in the US
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Table of Contents

1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Introduction 4
2.1 Diabetes 4
2.2 Epidemiology 4
2.2.1 Prevalence 4
2.2.2 Mortality 6
2.3 Etiology and Risk Factors 8
2.3.1 Obesity 8
2.3.2 Sedentary Lifestyle 8
2.3.3 Family History and Genetics 8
2.3.4 Ethnicity 8
2.3.5 Old Age 8
2.4 Economic Impact of Diabetes 8
2.5 Report Guidance 10
3 Type 2 Diabetes: Market Characterization 11
3.1 Type 2 Diabetes Market 11
3.2 Type 2 Diabetes Market Forecasts 12
3.3 Type 2 Diabetes Market: Drivers and Restraints 13
3.3.1 Drivers 13
3.3.2 Restraints 14
4 Classification of Diabetes 15
4.1 Types of Diabetes 15
4.1.1 Type 1 Diabetes 15
4.1.2 Type 2 Diabetes 15
4.1.3 Gestational Diabetes 15
4.2 Diabetes Complications 15
4.2.1 Cardiovascular Disease 15
4.2.2 Nephropathy 16
4.2.3 Neuropathy 16
4.2.4 Amputation 16
4.2.5 Retinopathy 16
5 Evolution of Anti-Diabetic Treatments 17
6 Medications 18
6.1 Insulin 18
6.2 Oral Medications 18
6.2.1 Sulfonylureas (SUR) 18
6.2.2 Biguanides (BGDs) 18
6.2.3 Alpha-Glucosidase Inhibitors (AGI) 20
6.2.4 Meglitinides 20
6.2.5 Thiazolidinediones (TZDs) 21
6.2.6 Dipeptidyl Peptidase IV (DPP- 4) Inhibitors 22
6.2.7 Oral Combination Therapy 22
6.3 Other Injectionable Medications 23
6.3.1 Pramlintide 23
6.3.2 Exenatide 23
6.4 Market Share as per Classes in Type 2 Diabetes 23
7 Cycloset 24
7.1 Introduction 24
7.2 Mechanism of Action 24
7.3 Clinical Studies 24
7.4 Approval History of Cycloset 25
7.5 Factors Affecting Sales of Cycloset 25
7.5.1 Low Risk of Cardiovascular Adverse Events 25
7.5.2 New Class of Drug 25
7.5.3 Lack of Presence in EU and Japan 25
7.6 Drug Evaluation 26
7.6.1 Drug Risk Benefit Score 26
7.6.2 Intensity of Competition 26
7.7 Sales Forecasts 27
7.7.1 Target Patient Pool 27
7.7.2 Dosing 27
7.7.3 Market Penetration 27
7.7.4 Annual Cost of Therapy 27
7.7.5 Sales Projections of Cycloset 27
8 Diabetes Market: Appendix 29
8.1 Market Definitions 29
8.2 List of Abberiviations 29
8.3 Research Methodology 30
8.3.1 Coverage 30
8.3.2 Secondary Research 30
8.3.3 Forecasting 30
8.3.4 Net Penetration of Drug 31
8.3.5 Net Annual Dosing 31
8.3.6 Annual Cost of Therapy 31
8.3.7 Primary Research 31
8.3.8 Expert Panels 32
8.4 Drug Sales Estimates Model 32
8.5 Contact Us 32
8.6 Disclaimer 32
8.7 Sources 33
1.1 List of Tables
Table 1: Diabetes, World, Prevalence Estimates for the age group 20-79 years (million), 2000-2030 4
Table 2: Diabetes, Top 10 Countries, by Prevalence (million), 2010 and 2030 6
Table 3: Diabetes, Top 10 Countries, Highest Health Expenditures ($bn),  2010 9
Table 4: Type 2 Diabetes, World, Major Marketed Drugs, 2010 11
Table 5: Type 2 Diabetes, World, Major Pipeline Products in Phase III 12
Table 6: Diabetes, Worldwide, Prevalence Estimates, 2010 and 2030 13
Table 7: Overweight*, Global, Prevalence Estimates in Males Aged 15 and above (%), 2005 14
Table 8: Diabetes Drugs Evolution 17
Table 9: Phase III Results 25
Table 10: Approval Details of Cycloset 25
Table 11: Drug Risk Benefit Score of Cycloset 26
Table 12: Cycloset, Type 2 Diabetes, The US, Sales Estimates ($m), 2010-2020 28
1.2 List of Figures
Figure 1: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2010 5
Figure 2: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2030 5
Figure 3: Diabetes, World, Mortality, 2010 6
Figure 4: Top 10 Causes of Mortality, Worldwide, 2008 7
Figure 5: Type 2 Diabetes, Global, Market Size Forecasts ($bn), 2010–2020 12
Figure 6: Mechanism of Action of Sulfonylurea 18
Figure 7: Mechanism of Action of Biguanide, Thiazolidinediones, Alpha-Glucosidase Inhibitors 19
Figure 8: Mechanism of Action of Metformin and  Alpha-Glucosidase Inhibitors 20
Figure 9: Mechanism of Action of Thiazolidinediones 21
Figure 10: Mechanism of Action of DPP IV Inhibitors 22
Figure 11: Type 2 Diabetes, Global, Market Share by Value, By Class (%), 2010 23
Figure 12: Cycloset , Type 2 Diabetes , The US, Sales Estimates ($m), 2010-2020 28

   top of page